VolitionRx Limited to Present at Multiple Investor Conferences in June
A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays
VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update
VolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update
Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe
Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory
VolitionRx Appoints David Vanston as Chief Financial Officer
Volition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States
VolitionRx Limited Announces the Formation of Volition America, Inc.
VolitionRx Limited Celebrates CE Mark Announcement By Ringing Closing Bell at the New York Stock Exchange
